The US ITC has officially launched a 337 investigation into antibody conjugated drugs, their components, and downstream products

On December 17, 2025, the United States International Trade Commission (ITC) voted to initiate a 337 investigation (investigation code: 337-TA-1466) on Certain Antibody Drug Conjugates and Components There of and Products Containing the Same.

On November 18, 2025, Abb Vie Inc., ImmunoGen, Inc., and ImmunoGen Switzerland GmbH filed a 337 investigation application with the US ITC, claiming that the product exported to, imported into, and sold in the United States violated US Section 337 (infringement of trade secrets), and requested the US ITC to issue a limited exclusion order or injunction.

Profound Bio US Co. of Seattle, WA, Jiangsu Profound Bio (Suzhou) Co., Ltd. of China, Genmab A/S of Denmark, Genmab B.V. of Netherlands, and Genmab US, Inc. of Plainsboro, NJ are listed as defendants.

The US International Trade Commission will determine the end date of the investigation within 45 days after filing the case. Except in cases where the United States Trade Representative vetoes a relief order based on policy reasons, the relief order issued by the United States International Trade Commission in the 337 case shall take effect from the date of issuance and shall have final effect on the 60th day after the date of issuance.

(Compiled from the official website of the United States International Trade Commission)